Literature DB >> 25203533

Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS).

Joseph A Boscarino1, Mei Lu, Anne C Moorman, Stuart C Gordon, Loralee B Rupp, Philip R Spradling, Eyasu H Teshale, Mark A Schmidt, Vinutha Vijayadeva, Scott D Holmberg.   

Abstract

UNLABELLED: Our objective was to assess the extent and risk factors for depression and poor physical health among patients with chronic hepatitis C virus (HCV) infection. We surveyed HCV-infected patients seen at four large healthcare systems participating in the Chronic Hepatitis Cohort Study (CHeCS). Survey data included demographics, depression and physical health measures, substance use history, current social support, recent stressor exposures, and, from the electronic medical record, treatment history, and Charlson Comorbidity Index scores. There were 4,781 respondents, who were a mean of 56.7 years old, 71% White, and 57% male. Altogether, 51.4% reported past injection drug use, 33.9% were current smokers, and 17.7% had abused alcohol in the previous year. Additionally, 47.4% had been previously treated for HCV and 14.8% had a 12-week sustained viral response (SVR) following HCV therapy. Overall, 29.7% of patients met criteria for current depression and 24.6% were in poor physical health. In multivariate analyses, significant predictors of depression and poor health included: male gender (versus female, odds ratios [ORs], 0.70 and 0.81), Black race (versus white, ORs, 0.60 and 0.61), having education less than high school (versus college, ORs, 1.81 and 1.54), being employed (versus not, ORs, 0.36 and 0.25), having high life stressors (versus low, ORs, 2.44 and 1.64), having low social support (versus high, ORs=2.78 and 1.40), and having high Charlson scores (versus none, ORs=1.58 and 2.12). Achieving a 12-week SVR was found to be protective for depression.
CONCLUSION: This large survey of U.S. HCV patients indicates the extent of adverse health behaviors and mental and physical comorbidities among these patients.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25203533      PMCID: PMC5675518          DOI: 10.1002/hep.27422

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

1.  New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality.

Authors:  Vijaya Sundararajan; Toni Henderson; Catherine Perry; Amanda Muggivan; Hude Quan; William A Ghali
Journal:  J Clin Epidemiol       Date:  2004-12       Impact factor: 6.437

2.  Mental health outcomes among vulnerable residents after Hurricane Sandy: implications for disaster research and planning.

Authors:  Joseph A Boscarino; Stuart N Hoffman; Richard E Adams; Charles R Figley; Ramon Solhkhah
Journal:  Am J Disaster Med       Date:  2014

3.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

4.  Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

Authors:  Zobair M Younossi; Maria Stepanova; Linda Henry; Edward Gane; Ira M Jacobson; Eric Lawitz; David Nelson; Fatema Nader; Sharon Hunt
Journal:  J Hepatol       Date:  2013-12-11       Impact factor: 25.083

5.  The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test.

Authors:  K Bush; D R Kivlahan; M B McDonell; S D Fihn; K A Bradley
Journal:  Arch Intern Med       Date:  1998-09-14

6.  PTSD onset and course following the World Trade Center disaster: findings and implications for future research.

Authors:  Joseph A Boscarino; Richard E Adams
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-03-07       Impact factor: 4.328

7.  Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself.

Authors:  Edna Strauss; Francisco Augusto Porto-Ferreira; Cesar de Almeida-Neto; Maria Cristina Dias Teixeira
Journal:  Clin Res Hepatol Gastroenterol       Date:  2013-11-14       Impact factor: 2.947

8.  Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work.

Authors:  Steven R Austin; Yu-Ning Wong; Robert G Uzzo; J Robert Beck; Brian L Egleston
Journal:  Med Care       Date:  2015-09       Impact factor: 2.983

9.  Screening for problem drinking: comparison of CAGE and AUDIT. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test.

Authors:  K A Bradley; K R Bush; M B McDonell; T Malone; S D Fihn
Journal:  J Gen Intern Med       Date:  1998-06       Impact factor: 5.128

10.  Risk factors for the development of depression in patients with hepatitis C taking interferon-α.

Authors:  Kimberley J Smith; Suzanne Norris; Cliona O'Farrelly; Shane M O'Mara
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-15       Impact factor: 2.570

View more
  29 in total

1.  Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes!

Authors:  Sandra A Springer; Carlos Del Rio
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

2.  Complementary and Alternative Medicine Use in United States Adults With Liver Disease.

Authors:  Jacqueline B Henson; Cristal L Brown; Shein-Chung Chow; Andrew J Muir
Journal:  J Clin Gastroenterol       Date:  2017-07       Impact factor: 3.062

3.  Mental and physical health status among chronic hepatitis B patients.

Authors:  Yihe G Daida; Joseph A Boscarino; Anne C Moorman; Mei Lu; Loralee B Rupp; Stuart C Gordon; Eyasu H Teshale; Mark A Schmidt; Philip R Spradling
Journal:  Qual Life Res       Date:  2020-01-14       Impact factor: 4.147

4.  Comparison of ICD-9 Codes for Depression and Alcohol Misuse to Survey Instruments Suggests These Codes Should Be Used with Caution.

Authors:  Joseph A Boscarino; Anne C Moorman; Loralee B Rupp; Yueren Zhou; Mei Lu; Eyasu H Teshale; Stuart C Gordon; Philip R Spradling; Mark A Schmidt; Connie Mah Trinacty; Yuna Zhong; Scott D Holmberg; Deborah Holtzman
Journal:  Dig Dis Sci       Date:  2017-09-06       Impact factor: 3.199

5.  Prospective Longitudinal Substance Use Patterns in Patients Preparing for Hepatitis C Treatment.

Authors:  Carol S North; David E Pollio; Omar T Sims; Mamta K Jain; Barry A Hong
Journal:  J Dual Diagn       Date:  2018-01-18

Review 6.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Authors:  Andrew M Moon; Amit G Singal; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-08       Impact factor: 11.382

7.  An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.

Authors:  Zobair M Younossi; Maria Stepanova; Linda Henry; Fatema Nader; Sharon Hunt
Journal:  Am J Gastroenterol       Date:  2016-03-29       Impact factor: 10.864

8.  Mental Health Disorders and Treatment Seeking Among Veterans in Non-VA Facilities: Results and Implications from the Veterans' Health Study.

Authors:  Joseph A Boscarino; Stuart N Hoffman; James M Pitcavage; Thomas G Urosevich
Journal:  Mil Behav Health       Date:  2015

Review 9.  Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings.

Authors:  Anne C Moorman; Loralee B Rupp; Stuart C Gordon; Yuna Zhong; Jian Xing; Mei Lu; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Eyasu H Teshale; Philip R Spradling; Scott D Holmberg
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

10.  A Systematic Comparison of African American and Non-African American Patients on Psychosocial Aspects of Hepatitis C Infection.

Authors:  Omar T Sims; Barry A Hong; Shaonin Ji; David E Pollio; Carol S North
Journal:  J Relig Health       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.